on agreement with AstraZeneca, along with MedImmune, its global biologics research and development arm, to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanized IgG4 antibody. In April 2015, AstraZeneca and MedImmune announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma. In May 2015, AstraZeneca plc and MedImmune, have entered into a collaboration with Innate Pharma SA to develop Innate's anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. In May 2015, The Montreal Heart Institute announced a collaboration with AstraZeneca to screen 80,000 samples for cardiovascular and diabetes genetic associated with cardiovascular diseases and diabetes, their complications and treatment outcomes. In May 2015, AstraZeneca (UK) has entered into a collaboration deal with Abbott for developing companion diagnostic tests in order to identify patients with severe asthma, who are highly likely to benefit from a candidate drug, tralokinumab. In May 2015, Astrazeneca (AZN) and Eli Lilly & Co. (LLY) said that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA), Eli Lilly's VEGF Receptor 2 antiangiogenic cancer medicine. In June 2015, AstraZeneca has launched a research and development (R&D) respiratory centre in the Spanish city of Barcelona. In July 2015, AstraZeneca and the University of Adelaide have announced an exciting new collaboration which will see 50 of AstraZeneca’s drug compounds passed to university researchers to study new therapies. In July 2015, Innate Pharma SA announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, received HSR clearance. In July 2015, Fujifilm Kyowa Kirin Biologics Co. Ltd. announced that it has entered into an agreement with AstraZeneca plc to establish a joint venture for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours. In July 2015, Charles River Laboratories International reported the extension of its strategic drug development partnership with AstraZeneca. Under the agreement, Charles River Laboratories International has extended its initial three-year partnership with AstraZeneca for an additional five-year period. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.
astrazeneca plc-spons adr (AZNN:Mexico)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151www.astrazeneca.com
|3M Co||$151.34 USD||-0.23|
|Abbott Laboratories||$50.69 USD||-0.08|
|Biogen Inc||$318.78 USD||+1.78|
|Eli Lilly & Co||$84.51 USD||-0.03|
|Valeant Pharmaceuticals International Inc||C$335.61 CAD||+4.75|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.